Cargando…
Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma
BACKGROUND: The concordance between mutations detected from plasma and tissue is critical for treatment choices of patients with advanced lung adenocarcinoma. METHODS: We prospectively analyzed the association of the serum tumor markers with the concordance between blood and tissue genomic profiles...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350084/ https://www.ncbi.nlm.nih.gov/pubmed/34430361 http://dx.doi.org/10.21037/tlcr-21-543 |
_version_ | 1783735676968108032 |
---|---|
author | Jiao, Xiao-Dong Ding, Li-Ren Zhang, Chuan-Tao Qin, Bao-Dong Liu, Ke Jiang, Lian-Ping Wang, Xi Lv, Li-Ting Ding, Hao Li, Dao-Ming Yang, Hui Chen, Xue-Qin Zhu, Wen-Yu Wu, Ying Ling, Yan He, Xi Liu, Jun Shao, Lin Wang, Hao-Zhe Chen, Yan Zheng, Jing-Jing Inui, Naoki Zang, Yuan-Sheng |
author_facet | Jiao, Xiao-Dong Ding, Li-Ren Zhang, Chuan-Tao Qin, Bao-Dong Liu, Ke Jiang, Lian-Ping Wang, Xi Lv, Li-Ting Ding, Hao Li, Dao-Ming Yang, Hui Chen, Xue-Qin Zhu, Wen-Yu Wu, Ying Ling, Yan He, Xi Liu, Jun Shao, Lin Wang, Hao-Zhe Chen, Yan Zheng, Jing-Jing Inui, Naoki Zang, Yuan-Sheng |
author_sort | Jiao, Xiao-Dong |
collection | PubMed |
description | BACKGROUND: The concordance between mutations detected from plasma and tissue is critical for treatment choices of patients with advanced lung adenocarcinoma. METHODS: We prospectively analyzed the association of the serum tumor markers with the concordance between blood and tissue genomic profiles from 185 patients with advanced lung adenocarcinoma. The concordance was defined according to 3 criteria. Class 1 included all targetable driver mutations in 8 genes; class 2 included class 1 mutations plus mutations in KRAS, STK11, and TP53; class 3 included class 2 mutations plus tumor mutation burden (TMB) status. RESULTS: Collectively, 150 out of 185 patients had mutations in both tissue and plasma samples, while one patient was mutation-negative for both, resulting a concordance of 81.6%. The concordance rate for class 1 mutations was 80%, and 65% and 69% for class 2 and class 3, respectively. Carbohydrate antigen 19-9 (CA19-9) or cytokeratin 19 (CYFRA21-1) levels higher than the normal upper limit predicted the concordance of tissue and blood results in class 1 (P=0.005, P=0.011), class 2 (P=0.011, P<0.001), and class 3 (P=0.001, P=0.014). In class 1, the cutoff values of CA19-9 were 30, 36, and 284 U/mL to reach the concordance thresholds of 90%, 95%, and 100%, respectively (P=0.032, P=0.003, P=0.043). For CYFRA21-1, the cutoff values were 6, 18, and 52 µg/L (P=0.005, P=0.051, P=0.354). In class 2, the cutoff values for CYFRA21-1 were 18, 22, and 52 µg/L (P=0.001, P=0.001, P=0.052). In class 3, the cutoff values for CA19-9 were 36, 39, and 85 U/mL (P=0.003, P=0.001, P=0.008). For CYFRA21-1, the cutoff values were 22, 52, and 52 µg/L (P=0.900, P>0.99, P>0.99). When the sum score for 4 serum tumor markers was greater than 35, both class 1, class 2, and class 3 reached a predictive threshold of 90%. CONCLUSIONS: Serum tumor markers can be used as easy and practical clinical predictors of concordance in mutation profiles between blood and tissue samples from patients with advanced lung adenocarcinoma. |
format | Online Article Text |
id | pubmed-8350084 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-83500842021-08-23 Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma Jiao, Xiao-Dong Ding, Li-Ren Zhang, Chuan-Tao Qin, Bao-Dong Liu, Ke Jiang, Lian-Ping Wang, Xi Lv, Li-Ting Ding, Hao Li, Dao-Ming Yang, Hui Chen, Xue-Qin Zhu, Wen-Yu Wu, Ying Ling, Yan He, Xi Liu, Jun Shao, Lin Wang, Hao-Zhe Chen, Yan Zheng, Jing-Jing Inui, Naoki Zang, Yuan-Sheng Transl Lung Cancer Res Original Article BACKGROUND: The concordance between mutations detected from plasma and tissue is critical for treatment choices of patients with advanced lung adenocarcinoma. METHODS: We prospectively analyzed the association of the serum tumor markers with the concordance between blood and tissue genomic profiles from 185 patients with advanced lung adenocarcinoma. The concordance was defined according to 3 criteria. Class 1 included all targetable driver mutations in 8 genes; class 2 included class 1 mutations plus mutations in KRAS, STK11, and TP53; class 3 included class 2 mutations plus tumor mutation burden (TMB) status. RESULTS: Collectively, 150 out of 185 patients had mutations in both tissue and plasma samples, while one patient was mutation-negative for both, resulting a concordance of 81.6%. The concordance rate for class 1 mutations was 80%, and 65% and 69% for class 2 and class 3, respectively. Carbohydrate antigen 19-9 (CA19-9) or cytokeratin 19 (CYFRA21-1) levels higher than the normal upper limit predicted the concordance of tissue and blood results in class 1 (P=0.005, P=0.011), class 2 (P=0.011, P<0.001), and class 3 (P=0.001, P=0.014). In class 1, the cutoff values of CA19-9 were 30, 36, and 284 U/mL to reach the concordance thresholds of 90%, 95%, and 100%, respectively (P=0.032, P=0.003, P=0.043). For CYFRA21-1, the cutoff values were 6, 18, and 52 µg/L (P=0.005, P=0.051, P=0.354). In class 2, the cutoff values for CYFRA21-1 were 18, 22, and 52 µg/L (P=0.001, P=0.001, P=0.052). In class 3, the cutoff values for CA19-9 were 36, 39, and 85 U/mL (P=0.003, P=0.001, P=0.008). For CYFRA21-1, the cutoff values were 22, 52, and 52 µg/L (P=0.900, P>0.99, P>0.99). When the sum score for 4 serum tumor markers was greater than 35, both class 1, class 2, and class 3 reached a predictive threshold of 90%. CONCLUSIONS: Serum tumor markers can be used as easy and practical clinical predictors of concordance in mutation profiles between blood and tissue samples from patients with advanced lung adenocarcinoma. AME Publishing Company 2021-07 /pmc/articles/PMC8350084/ /pubmed/34430361 http://dx.doi.org/10.21037/tlcr-21-543 Text en 2021 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Jiao, Xiao-Dong Ding, Li-Ren Zhang, Chuan-Tao Qin, Bao-Dong Liu, Ke Jiang, Lian-Ping Wang, Xi Lv, Li-Ting Ding, Hao Li, Dao-Ming Yang, Hui Chen, Xue-Qin Zhu, Wen-Yu Wu, Ying Ling, Yan He, Xi Liu, Jun Shao, Lin Wang, Hao-Zhe Chen, Yan Zheng, Jing-Jing Inui, Naoki Zang, Yuan-Sheng Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma |
title | Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma |
title_full | Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma |
title_fullStr | Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma |
title_full_unstemmed | Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma |
title_short | Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma |
title_sort | serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350084/ https://www.ncbi.nlm.nih.gov/pubmed/34430361 http://dx.doi.org/10.21037/tlcr-21-543 |
work_keys_str_mv | AT jiaoxiaodong serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma AT dingliren serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma AT zhangchuantao serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma AT qinbaodong serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma AT liuke serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma AT jianglianping serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma AT wangxi serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma AT lvliting serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma AT dinghao serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma AT lidaoming serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma AT yanghui serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma AT chenxueqin serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma AT zhuwenyu serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma AT wuying serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma AT lingyan serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma AT hexi serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma AT liujun serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma AT shaolin serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma AT wanghaozhe serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma AT chenyan serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma AT zhengjingjing serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma AT inuinaoki serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma AT zangyuansheng serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma |